HomeCompareCVALF vs EQR

CVALF vs EQR: Dividend Comparison 2026

CVALF yields 8.37% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $13.0K in total portfolio value· pulled ahead in Year 4
10 years
CVALF
CVALF
● Live price
8.37%
Share price
$1.27
Annual div
$0.11
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.8K
Annual income
$1,420.80
Full CVALF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — CVALF vs EQR

📍 EQR pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCVALFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CVALF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CVALF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CVALF
Annual income on $10K today (after 15% tax)
$711.52/yr
After 10yr DRIP, annual income (after tax)
$1,207.68/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $3,446.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CVALF + EQR for your $10,000?

CVALF: 50%EQR: 50%
100% EQR50/50100% CVALF
Portfolio after 10yr
$41.3K
Annual income
$3,448.20/yr
Blended yield
8.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CVALF
No analyst data
Altman Z
5.0
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CVALF buys
0
EQR buys
0
No recent congressional trades found for CVALF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCVALFEQR
Forward yield8.37%5.87%
Annual dividend / share$0.11$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$34.8K$47.8K
Annual income after 10y$1,420.80$5,475.61
Total dividends collected$11.3K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CVALF vs EQR ($10,000, DRIP)

YearCVALF PortfolioCVALF Income/yrEQR PortfolioEQR Income/yrGap
1$11,537$837.09$11,380$679.82+$157.00CVALF
2$13,247$902.57$13,014$837.25+$233.00CVALF
3$15,143$968.57$14,961$1,036.20+$182.00CVALF
4← crossover$17,238$1,034.75$17,297$1,289.22$59.00EQR
5$19,545$1,100.83$20,121$1,613.15$576.00EQR
6$22,080$1,166.53$23,561$2,030.84$1.5KEQR
7$24,857$1,231.60$27,783$2,573.54$2.9KEQR
8$27,893$1,295.80$33,013$3,284.39$5.1KEQR
9$31,205$1,358.93$39,547$4,223.51$8.3KEQR
10$34,810$1,420.80$47,791$5,475.61$13.0KEQR

CVALF vs EQR: Complete Analysis 2026

CVALFStock

Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has 3 proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. Its products include wound care dressings; surgical and peri-operative products; and infection management products. The company offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.

Full CVALF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CVALF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CVALF vs SCHDCVALF vs JEPICVALF vs OCVALF vs KOCVALF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.